Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia

BeyondSpring Inc (NASDAQ:BYSI) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Annual Meeting and Exposition. 

  • The comparison was made between cancer patients receiving plinabulin 40 mg (n=228) or not receiving plinabulin (n=172) and with all patients receiving myelosuppressive chemotherapy. 
  • Plinabulin 40 mg was given 30 minutes after chemotherapy.
  • Plinabulin rapidly (within 24 hours) reversed chemo-induced myelosuppression in both the PROTECTIVE-1 and 2 studies. 
  • Plinabulin-mediated increases in cell numbers are dose-dependent and correlated among myeloid, lymphoid, and erythroid lineages cells.
  • Related Link: BeyondSpring Shares Crater After FDA Rejects Plinabulin Application.
  • Price Action: BYSI shares are up 4.91% at $4.27 during the market session on the last check Wednesday.
  • Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.